

**REMARKS**

The amendments to the specification submitted above are simply to correct the symbols in the specification to correspond with those symbols actually shown in the respective figures.

In particular, in the figure reference to figure 5 on page 8, line 2, the symbol in brackets following the word "activity" should be closed circle i.e. (•).

For figure 12, in the Figure reference at page 10, line 6, the symbols should be as follows: "negative (• and filled bars) and recombinant (○ and open bars) sphingosine kinases were..."

Figure 13 figure legend at page 10, lines 20-23, the symbols should be as follows: *B*, substrate kinetics of the recombinant human sphingosing kinase with sphingosine (•) and D-*erythro*-dihydrosphingosine (○) as substrates. *C*, Kinetics of inhibition of the recombinant human sphingosine kinase with *N,N,N*-trimethylsphingosine at 5 μM (○) and 25 μM (▼), and in the absence of *N,N,N*-trimethylsphingosine (•).


As the above corrective changes should have no effect whatsoever on examination, applicants request the Examiner to exercise her discretion and enter such amendments as corrective amendments.

In the Office Action of July 1, 2005, the Examiner requested copies of the priority documents. New certified copies have now been obtained and they are enclosed herewith. Applicants again respectfully claim priority. Acknowledgement by the PTO of the receipt of applicants' papers filed under Section 119 would be appreciated.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant

By



Sheridan Neimark  
Registration No. 20,520

SN:kg  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528  
G:\BN\B\Blaj\Pitson1A\pto\Supplemental Reply 10NOV05.doc